世界の良性前立腺肥大症治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Benign Prostatic Hyperplasia Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-2104Z02102
• 出版社/出版日：GlobalInfoResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、100ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥494,160 (USD3,480)	▷ お問い合わせ
Multi User	￥741,240 (USD5,220)	▷ お問い合わせ
Corporate User	￥988,320 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料では、良性前立腺肥大症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。良性前立腺肥大症治療の種類別市場規模（アルファ遮断薬、5-アルファレダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他）、用途別市場規模（単剤療法、併用薬物療法）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・良性前立腺肥大症治療の市場概要
・企業情報（企業概要、製品概要、販売量、価格、売上）：Abbott Laboratories、Allergan plc、Astellas Pharma、Boehringer Ingelheim Pharma GmbH and Co. KG、Eli Lilly and Company、GlaxoSmithKline plc、Merck and Co.、Pfizer、Sanofi、Teva Pharmaceutical Industries Limited
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年：アルファ遮断薬、5-アルファレダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他
・用途別分析2016年-2026年：単剤療法、併用薬物療法
・良性前立腺肥大症治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ
・良性前立腺肥大症治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア
・良性前立腺肥大症治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア
・良性前立腺肥大症治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン
・良性前立腺肥大症治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Benign Prostatic Hyperplasia Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Benign Prostatic Hyperplasia Therapeutics size is estimated to be USD 7532.5 million in 2025 from USD 6626.4 million in 2019, with a change XX% between 2019 and 2020. The global Benign Prostatic Hyperplasia Therapeutics market size is expected to grow at a CAGR of 3.3% for the next five years.

Market segmentation
Benign Prostatic Hyperplasia Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others

Market segment by Application, can be divided into
Mono Drug Therapy
Combination Drug Therapy

Market segment by players, this report covers
Abbott Laboratories
Allergan plc
Astellas Pharma
Boehringer Ingelheim Pharma GmbH and Co. KG
Eli Lilly and Company
GlaxoSmithKline plc
Merck and Co.
Pfizer
Sanofi
Teva Pharmaceutical Industries Limited

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

1 Market Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Therapeutics
1.2 Classification of Benign Prostatic Hyperplasia Therapeutics by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type in 2020
1.2.3 Alpha Blocker
1.2.4 5-Alpha Reductase Inhibitor
1.2.5 Phosphodiesterase-5 Inhibitor
1.2.6 Others
1.3 Global Benign Prostatic Hyperplasia Therapeutics Market by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Mono Drug Therapy
1.3.3 Combination Drug Therapy
1.4 Global Benign Prostatic Hyperplasia Therapeutics Market Size & Forecast
1.5 Global Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast by Region
1.5.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Benign Prostatic Hyperplasia Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Benign Prostatic Hyperplasia Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Benign Prostatic Hyperplasia Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Benign Prostatic Hyperplasia Therapeutics Market Drivers
1.6.2 Benign Prostatic Hyperplasia Therapeutics Market Restraints
1.6.3 Benign Prostatic Hyperplasia Therapeutics Trends Analysis
2 Company Profiles
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business
2.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.1.4 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Abbott Laboratories Recent Developments and Future Plans
2.2 Allergan plc
2.2.1 Allergan plc Details
2.2.2 Allergan plc Major Business
2.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.2.4 Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Allergan plc Recent Developments and Future Plans
2.3 Astellas Pharma
2.3.1 Astellas Pharma Details
2.3.2 Astellas Pharma Major Business
2.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.3.4 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Astellas Pharma Recent Developments and Future Plans
2.4 Boehringer Ingelheim Pharma GmbH and Co. KG
2.4.1 Boehringer Ingelheim Pharma GmbH and Co. KG Details
2.4.2 Boehringer Ingelheim Pharma GmbH and Co. KG Major Business
2.4.3 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.4.4 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments and Future Plans
2.5 Eli Lilly and Company
2.5.1 Eli Lilly and Company Details
2.5.2 Eli Lilly and Company Major Business
2.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.5.4 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Eli Lilly and Company Recent Developments and Future Plans
2.6 GlaxoSmithKline plc
2.6.1 GlaxoSmithKline plc Details
2.6.2 GlaxoSmithKline plc Major Business
2.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.6.4 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 GlaxoSmithKline plc Recent Developments and Future Plans
2.7 Merck and Co.
2.7.1 Merck and Co. Details
2.7.2 Merck and Co. Major Business
2.7.3 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.7.4 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Merck and Co. Recent Developments and Future Plans
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.8.4 Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Pfizer Recent Developments and Future Plans
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.9.4 Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Sanofi Recent Developments and Future Plans
2.10 Teva Pharmaceutical Industries Limited
2.10.1 Teva Pharmaceutical Industries Limited Details
2.10.2 Teva Pharmaceutical Industries Limited Major Business
2.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product and Solutions
2.10.4 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Teva Pharmaceutical Industries Limited Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Benign Prostatic Hyperplasia Therapeutics Players Market Share
3.2.2 Top 10 Benign Prostatic Hyperplasia Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Benign Prostatic Hyperplasia Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Benign Prostatic Hyperplasia Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Benign Prostatic Hyperplasia Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2016-2026)
6.2 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2026)
6.3 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Country
6.3.1 North America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2016-2026)
7.2 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2026)
7.3 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Country
7.3.1 Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size by Region
8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Region (2016-2026)
8.3.2 China Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2016-2026)
9.2 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2026)
9.3 South America Benign Prostatic Hyperplasia Therapeutics Market Size by Country
9.3.1 South America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size by Country
10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Benign Prostatic Hyperplasia Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Benign Prostatic Hyperplasia Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
Table 7. Abbott Laboratories Major Business
Table 8. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 9. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Allergan plc Corporate Information, Head Office, and Major Competitors
Table 11. Allergan plc Major Business
Table 12. Allergan plc Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 13. Allergan plc Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Astellas Pharma Corporate Information, Head Office, and Major Competitors
Table 15. Astellas Pharma Major Business
Table 16. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 17. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Boehringer Ingelheim Pharma GmbH and Co. KG Corporate Information, Head Office, and Major Competitors
Table 19. Boehringer Ingelheim Pharma GmbH and Co. KG Major Business
Table 20. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 21. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 23. Eli Lilly and Company Major Business
Table 24. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 25. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. GlaxoSmithKline plc Corporate Information, Head Office, and Major Competitors
Table 27. GlaxoSmithKline plc Major Business
Table 28. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 29. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Merck and Co. Corporate Information, Head Office, and Major Competitors
Table 31. Merck and Co. Major Business
Table 32. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 33. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Pfizer Corporate Information, Head Office, and Major Competitors
Table 35. Pfizer Major Business
Table 36. Pfizer Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 37. Pfizer Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Sanofi Corporate Information, Head Office, and Major Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 41. Sanofi Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Teva Pharmaceutical Industries Limited Corporate Information, Head Office, and Major Competitors
Table 43. Teva Pharmaceutical Industries Limited Major Business
Table 44. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product and Solutions
Table 45. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 47. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players (2019-2021)
Table 48. Breakdown of Benign Prostatic Hyperplasia Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Benign Prostatic Hyperplasia Therapeutics Players Head Office, Products and Services Provided
Table 50. Benign Prostatic Hyperplasia Therapeutics Mergers & Acquisitions in the Past Five Years
Table 51. Benign Prostatic Hyperplasia Therapeutics New Entrants and Expansion Plans
Table 52. Global Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 53. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Type (2016-2021)
Table 54. Global Benign Prostatic Hyperplasia Therapeutics Revenue Forecast by Type (2021-2026)
Table 55. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2021)
Table 56. Global Benign Prostatic Hyperplasia Therapeutics Revenue Forecast by Application (2021-2026)
Table 57. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Benign Prostatic Hyperplasia Therapeutics Picture
Figure 2. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type in 2020
Figure 3. Alpha Blocker
Figure 4. 5-Alpha Reductase Inhibitor
Figure 5. Phosphodiesterase-5 Inhibitor
Figure 6. Others
Figure 7. Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Application in 2020
Figure 8. Mono Drug Therapy Picture
Figure 9. Combination Drug Therapy Picture
Figure 10. Global Benign Prostatic Hyperplasia Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Benign Prostatic Hyperplasia Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Region (2016-2026)
Figure 13. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Region in 2020
Figure 14. North America Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Benign Prostatic Hyperplasia Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Benign Prostatic Hyperplasia Therapeutics Market Drivers
Figure 19. Benign Prostatic Hyperplasia Therapeutics Market Restraints
Figure 20. Benign Prostatic Hyperplasia Therapeutics Market Trends
Figure 21. Abbott Laboratories Recent Developments and Future Plans
Figure 22. Allergan plc Recent Developments and Future Plans
Figure 23. Astellas Pharma Recent Developments and Future Plans
Figure 24. Boehringer Ingelheim Pharma GmbH and Co. KG Recent Developments and Future Plans
Figure 25. Eli Lilly and Company Recent Developments and Future Plans
Figure 26. GlaxoSmithKline plc Recent Developments and Future Plans
Figure 27. Merck and Co. Recent Developments and Future Plans
Figure 28. Pfizer Recent Developments and Future Plans
Figure 29. Sanofi Recent Developments and Future Plans
Figure 30. Teva Pharmaceutical Industries Limited Recent Developments and Future Plans
Figure 32. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players in 2020
Figure 33. Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players Benign Prostatic Hyperplasia Therapeutics Revenue Market Share in 2020
Figure 35. Global Top 10 Players Benign Prostatic Hyperplasia Therapeutics Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Type in 2020
Figure 38. Global Benign Prostatic Hyperplasia Therapeutics Market Share Forecast by Type (2021-2026)
Figure 39. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Application in 2020
Figure 40. Global Benign Prostatic Hyperplasia Therapeutics Market Share Forecast by Application (2021-2026)
Figure 41. North America Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2016-2026)
Figure 42. North America Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2016-2026)
Figure 43. North America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 44. United States Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2016-2026)
Figure 48. Europe Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2016-2026)
Figure 49. Europe Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 50. Germany Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Region (2016-2026)
Figure 58. China Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2016-2026)
Figure 65. South America Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2016-2026)
Figure 66. South America Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Country (2016-2026)
Figure 72. Turkey Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE Benign Prostatic Hyperplasia Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source

以下、関連資料のご紹介

世界の良性前立腺肥大症検査市場規模・現状・予測（2021年-2027年）

Global Benign Prostatic Hyperplasia Testing Market Size, Status and Forecast 2021-2027
QYR2104Z0742 2021年4月 90Pages
QYResearch社発行の本調査資料では、良性前立腺肥大症検査のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（尿検査、前立腺特異抗原（PSA）血液検査、尿流動態検査、膀胱鏡検査）、用途別市場規模（病院、診断センター、クリニック、研究機関）、主...

世界の良性前立腺肥大症市場規模・現状・予測（2021年-2027年）

Global Benign Prostatic Hyperplasia Market Size, Status and Forecast 2021-2027
QYR2104Z0741 2021年4月 99Pages
QYResearch社発行の本調査資料では、良性前立腺肥大症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（薬物療法、透析、その他）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、...

世界の処方皮膚科治療市場 2021：企業別、地域別、種類・用途別

Global Prescription Dermatology Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z11463 2021年4月 108Pages
当調査資料では、処方皮膚科治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。処方皮膚科治療の種類別市場規模（真菌感染症薬、皮膚がん薬、にきび＆酒皶薬、乾癬薬、皮膚炎＆脂漏症薬）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北...

世界の不眠症治療薬市場 2021：企業別、地域別、種類・用途別

Global Insomnia Therapeutics Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z07726 2021年4月 104Pages
当調査資料では、不眠症治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。不眠症治療薬の種類別市場規模（ベンゾジアゼピン系、非ベンゾジアゼピン系、抗うつ剤、オレキシン拮抗薬、メラトニン拮抗薬、その他）、用途別市場規模（処方箋、店頭（OTC））、地域別...

世界の急性リンパ芽球性白血病治療薬市場 2021：企業別、地域別、種類・用途別

Global Acute Lymphoblastic Leukemia Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z00329 2021年4月 121Pages
当調査資料では、急性リンパ芽球性白血病治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。急性リンパ芽球性白血病治療薬の種類別市場規模（化学療法、標的療法、放射線療法、幹細胞移植）、用途別市場規模（病院、薬局）、地域別市場規模（北米、アメリカ、ヨーロ...

世界の急性リンパ性/リンパ芽球性白血病治療薬市場 2021：企業別、地域別、種類・用途別

Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z00332 2021年4月 120Pages
当調査資料では、急性リンパ性/リンパ芽球性白血病治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。急性リンパ性/リンパ芽球性白血病治療薬の種類別市場規模（化学療法、標的療法、放射線療法、幹細胞移植）、用途別市場規模（病院、薬局）、地域別市場規模（北...

世界のNK（ナチュラルキラー）細胞療法市場 2021：企業別、地域別、種類・用途別

Global Natural Killer (NK) Cell Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z09818 2021年4月 107Pages
当調査資料では、NK（ナチュラルキラー）細胞療法のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。NK（ナチュラルキラー）細胞療法の種類別市場規模（モガムリズマブ、ロルボツズマブメルタンシン、その他）、用途別市場規模（がん、心血管疾患、その他）、地域別市...

世界のがん治療・支持療法薬市場 2021：企業別、地域別、種類・用途別

Global Cancer Therapeutics and Supportive Care Drugs Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z02678 2021年4月 103Pages
当調査資料では、がん治療・支持療法薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。がん治療・支持療法薬の種類別市場規模（がん治療薬、支持療法薬）、用途別市場規模（病院、小売薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南ア...

世界の真菌感染症治療薬市場 2021：企業別、地域別、種類・用途別

Global Antifungal infection Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-2104Z00975 2021年4月 123Pages
当調査資料では、真菌感染症治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。真菌感染症治療薬の種類別市場規模（ポリエン、エキノカンジン、アゾール、アリルアミン、その他薬剤）、用途別市場規模（粉末、ペースト、軟膏、医薬品、その他）、地域別市場規模（北...

世界の痙性斜頸治療市場規模・現状・予測（2021年-2027年）

Global Cervical Dystonia Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z1251 2021年4月 92Pages
QYResearch社発行の本調査資料では、痙性斜頸治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ボツリヌス毒素、薬物、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中...

世界の良性前立腺肥大症検査市場規模・現状・予測（2021年-2027年） Benign prostatic hyperplasia (BPH) is a condition occurring in men when the prostate gland is enlarged. Benign prostatic hyperplasia is also termed as benign prostatic hypertrophy or benign prostatic obstruction. Prostate gland grows in primarily two phases, firstly during puberty when the size of t…
世界の良性前立腺肥大症市場規模・現状・予測（2021年-2027年） Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving …
世界の小児てんかん治療薬市場規模・現状・予測（2021年-2027年） Epilepsy is one of the most common and challenging neurologic disorders affecting children. Pediatric epilepsies present particular challenges, including correct diagnoses, comorbidities and interactions with developmental processes in the brain. Market Analysis and Insights: Global Pediatric Epilep…
世界の血友病治療市場規模・現状・予測（2021年-2027年） Hemophilia is a rare, inherited disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. These proteins work with platelets i.e. small blood cell fragments that form in the bone marr…
世界の血友病治療市場規模・現状・予測（2021年-2027年） Hemophilia is a rare, inherited disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. These proteins work with platelets i.e. small blood cell fragments that form in the bone marr…